Bristol Myers Squibb (NYSE: BMY) has posted better-than-expected second-quarter 2025 results, driven by strong sales of its blood thinner Eliquis (apixaban) and cancer treatments Opdivo (nivolumab) and Revlimid (lenalidomide).

Bristol Myers Squibb surpassed analyst expectations with a strong Q2, as notable brands Eliquis, Opdivo, and Revlimid drove sales. Despite losing patent protections, revenue rose 1% to $12.3 billion.

Bristol-Myers Squibb Company (NYSE:BMY) is scheduled to announce Q2 earnings results on July 31st, before markets open. Analysts expect the company’s key metrics to see a year-on-year decline. EPS is estimated to see a 45.